2212 GMT - Pathology services provider Healius is in the recovery room, but Barrenjoey is skeptical that the company can reach performance targets laid out at its investor day yesterday. Healius wants to grow revenue at 6% and make a high-single-digit Ebit margin by FY 2027. Analyst Saul Hadassin says this implies Ebit growing at a compound annual rate of 120% from FY 2025-FY 2027. "While we anticipate an improvement in operating performance, this target looks difficult to deliver, particularly in light of looming cuts to VitB12/mid-stream urine tests," Barrenjoey says. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
March 27, 2025 18:12 ET (22:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。